6.
Lai C, Van den Ham R, Mol J, Teske E
. Immunostaining of the androgen receptor and sequence analysis of its DNA-binding domain in canine prostate cancer. Vet J. 2008; 181(3):256-60.
DOI: 10.1016/j.tvjl.2008.04.009.
View
7.
Tang X, Sui X, Weng L, Liu Y
. SNAIL1: Linking Tumor Metastasis to Immune Evasion. Front Immunol. 2021; 12:724200.
PMC: 8669501.
DOI: 10.3389/fimmu.2021.724200.
View
8.
Brand L, Dehm S
. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Curr Drug Targets. 2013; 14(4):441-9.
PMC: 3957184.
DOI: 10.2174/1389450111314040005.
View
9.
Lei Q, Jiao J, Xin L, Chang C, Wang S, Gao J
. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006; 9(5):367-78.
DOI: 10.1016/j.ccr.2006.03.031.
View
10.
Gloyna R, Siiteri P, Wilson J
. Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog. J Clin Invest. 1970; 49(9):1746-53.
PMC: 322658.
DOI: 10.1172/JCI106392.
View
11.
Leung J, Sadar M
. Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Front Endocrinol (Lausanne). 2017; 8:2.
PMC: 5239799.
DOI: 10.3389/fendo.2017.00002.
View
12.
Gao S, Gao Y, He H, Han D, Han W, Avery A
. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016; 17(4):966-976.
PMC: 5123835.
DOI: 10.1016/j.celrep.2016.09.064.
View
13.
Vasilatis D, Ghosh P
. Clinicopathologic Characterization of Prostatic Cancer in Dogs. Animals (Basel). 2024; 14(4).
PMC: 10886256.
DOI: 10.3390/ani14040588.
View
14.
Fonseca-Alves C, Rodrigues M, de Moura V, Rogatto S, Laufer-Amorim R
. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis. Microsc Res Tech. 2013; 76(12):1250-6.
DOI: 10.1002/jemt.22292.
View
15.
Yu C, Zheng H, Liu X, Xie G
. The Analysis of E-Cadherin, N-Cadherin, Vimentin, HER-2, CEA, CA15-3 and SF Expression in the Diagnosis of Canine Mammary Tumors. Animals (Basel). 2022; 12(21).
PMC: 9657150.
DOI: 10.3390/ani12213050.
View
16.
Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M, Motta M
. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res. 2003; 14(2):101-12.
DOI: 10.3727/000000003108748658.
View
17.
Albrizio M, Siniscalchi M, Sasso R, Quaranta A
. Effects of the environment on dog semen parameters and testosterone concentration. Theriogenology. 2013; 80(7):800-4.
DOI: 10.1016/j.theriogenology.2013.07.005.
View
18.
van de Merbel A, van der Horst G, Buijs J, van der Pluijm G
. Protocols for Migration and Invasion Studies in Prostate Cancer. Methods Mol Biol. 2018; 1786:67-79.
DOI: 10.1007/978-1-4939-7845-8_4.
View
19.
Katzenwadel A, Wolf P
. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett. 2015; 367(1):12-7.
DOI: 10.1016/j.canlet.2015.06.021.
View
20.
Evans M, Smith-Jones P, Wongvipat J, Navarro V, Kim S, Bander N
. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011; 108(23):9578-82.
PMC: 3111331.
DOI: 10.1073/pnas.1106383108.
View